MedWatch

Investors: Novo Nordisk's obesity efforts will lead to growth

Obesity will continue to be a huge health problem, which means a lot of growth potential for the company, one analyst says.

Photo: Novo Nordisk / PR

Danish firm Novo Nordisk's share price has experienced a boost on the stock exchange over the past few months, and the party is far from over.

Investors and analysts believe that the company's venture into the obesity market will be rewarded with large growth, Danish business daily Børsen reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs